

96. (Amended) The hybridoma of Claim 78 or 83, wherein said hybridoma produces a monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human CD4⁺ T lymphocytes and activated human CD8⁺ T lymphocytes.

97. (Twice amended) A method of producing a human 8F4 polypeptide-specific monoclonal antibody, comprising: culturing an antibody-secreting hybridoma obtained by fusion of a myeloma cell line cell with a spleen cell of a mouse immunized with an antigen comprising a human 8F4 polypeptide, wherein said human 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE, and wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539; such that the monoclonal antibody is produced.

Please add the following new claims:

99. (New) Hybridoma cell line deposited with the DSMZ and assigned accession no. DSM ACC2539.

100. (New) A monoclonal antibody 8F4 produced by the hybridoma cell line of claim 99.

REMARKS

Claims 71-76, 78-83, 85, 86, and 88-98 were pending in this application.

Claims 71, 76, 78, 83, 85, 86 and 89-97 have been amended to more particularly point out and distinctly claim that which Applicant regards as the present invention. In particular, claims 71, 76, 78, 83, 85, 86 and 97 have been amended to recited that the human 8F4

polypeptide is recognized by the antibody deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH ("DSMZ") and assigned accession no. DSM ACC2539. Claims 89-96 have been amended to recite additional claim dependencies. Claims 98 and 100 have been added to claims the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539 and the antibody secreted by said hybridoma, respectively. The specification has been amended to provide a sequence identifier for the sequence at page 19, line 30 of the specification. No new matter has been added.

Entry of the amendments and remarks made herein is respectfully requested. Following entry of the amendments made herein, claims 71-76, 78-83, 85, 86, and 88-100 will be pending in the present application.

Respectfully submitted,

Date April 19, 2002

Laura A. Coruzzi 30,742
(Reg. No.)

By: Muna Abu-Shaar
Muna Abu-Shaar
Limited Recognition Under 37 C.F.R. § 10.9(b)
Copy of Certificate Enclosed
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures